



Company Announcement no. 1/2009

To: NASDAQ OMX Copenhagen A/S

Hørsholm, Denmark, January 27, 2009

### Major Shareholder Announcements

Hørsholm, Denmark, 27 January 2009; In accordance with Section 29 of the Securities Trading Act LifeCycle Pharma A/S (OMX: LCP) today announced that LCP has received a notification from H. Lundbeck A/S that it has decreased its shareholdings in LCP from 15,313,816 shares, corresponding to 27.21%, to 0 shares.

At the same time, LCP has received a notification that LFI A/S, 100 % owned by the Lundbeck Foundation, now owns 15,878,066 shares, corresponding to 28.21%.

#### For more information, please contact:

LifeCycle Pharma A/S

Dr. Jim New  
President & Chief Executive Officer  
Phone: +45 7033 3300  
Email: [JSN@lcpharma.com](mailto:JSN@lcpharma.com)

Or

Peter Schøtt Knudsen  
Head of Investor Relations  
Phone: + 45 20553817  
Email: [PSK@lcpharma.com](mailto:PSK@lcpharma.com)

#### About LifeCycle Pharma A/S (LCP)

*Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging specialty pharmaceutical company. Clinical development is the core of LCP's effort to develop a product portfolio which includes products for immunosuppression, specifically organ transplantation, and products to combat certain cardiovascular diseases. As a fully integrated company, LCP adapts new technologies on a fast commercial timetable. LCP's unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability – at low-scale up costs – not only for a broad spectrum of drugs already on the market but also for new chemical entities. LCP has a cholesterol-lowering product, Fenoglide™, currently on the U.S. market and a diversified near- and medium-term pipeline with five product candidates in clinical trials and one in preclinical development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further information, please visit [www.lcpharma.com](http://www.lcpharma.com).*